GLP-1 receptor agonist: difference between revisions
Diff·revision 18 → 19·20:38, 28 Jan 2025
Difference between revision 18 and revision 19 of GLP-1 receptor agonist. 7 lines changed; the page grew by 1,083 bytes.
| Revision 18 — 21:15, 8 Jan 2025 GsCouplingGil (talk) attribute the mechanism claim to the review rather than stating it flatly 8,171 bytes +49 | Revision 19 — 20:38, 28 Jan 2025 MolarMassMaeve (talk) add the excipient list from the labelling 9,254 bytes +1,083 | ||
|---|---|---|---|
| 51 | Cardiovascular outcome trials have shown benefit for several members. The [[SELECT trial|SELECT]] trial reported a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity but without diabetes, and the [[FLOW trial|FLOW]] trial reported slowing of kidney-disease progression.{{r|lincoff2023}} These are outcome findings for specific molecules at specific doses and are not properties of the class as a whole; extrapolation between members is not supported by the trial evidence. | 51 | Cardiovascular outcome trials have shown benefit for several members. The [[SELECT trial|SELECT]] trial reported a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity but without diabetes, and the [[FLOW trial|FLOW]] trial reported slowing of kidney-disease progression.{{r|lincoff2023}} These are outcome findings for specific molecules at specific doses and are not properties of the class as a whole; extrapolation between members is not supported by the trial evidence. |
| 52 | 52 | ||
| + | 53 | Effect sizes reported in trials are means. Individual response is broadly distributed, and a substantial minority of participants in every published programme lose less than 5% of body weight. The determinants of that variation are not established.{{r|wilding2021}} | |
| + | 54 | ||
| + | 55 | == Adverse effects and tolerability == | |
| + | 56 | Gastrointestinal events dominate. Nausea, vomiting, diarrhoea and constipation are reported by between 20% and 45% of participants depending on agent and dose, are most frequent during escalation, and diminish with time at a stable dose. They are the commonest reason for discontinuation.{{r|drucker2018}} A fuller treatment is given at [[Adverse effects of GLP-1 receptor agonists]]. | |
| + | 57 | ||
| + | 58 | Less common but clinically significant concerns include gallbladder disease, acute pancreatitis, and — on the basis of rodent carcinogenicity data — a labelled contraindication in people with a personal or family history of medullary thyroid carcinoma. Delayed gastric emptying has prompted revised guidance on [[Aspiration risk under anaesthesia|preoperative fasting]].{{r|nauck2016}} | |
| + | 59 | ||
| 53 | == References == | 60 | == References == |
| 54 | {{reflist}} | 61 | {{reflist}} |